Background
The human body generates an immune response to tumors, but it is generally ineffective at causing tumor destruction. One possible reason is that T-cell activation will not occur until two separate signals are received by the cell. The first signal is specific antigen-recognition, which requires T-cell receptors to recognize and bind to major histocompatibility complex (MHC) molecules of antigen-presenting cells (APCs). The second signal is nonspecific and antigen-independent, generated by the interaction between CD28 on the T-cell surface and its ligands CD80 and CD86 on the APCs [
1‐
4]. The CD28 costimulatory pathway plays a critical role in the induction and regulation of autoreactive T-cells. Cytotoxic T-lymphocyte antigen 4 (CTLA-4), a CD28 homologue, is a glycoprotein expressed on activated T-cells that has a high binding affinity with the molecule B7, primarily expressed on APCs [
5‐
8]. Though CTLA-4 shares the same costimulatory ligands as CD28, it delivers a different costimulatory signal. While CTLA-4 is a well documented T-cell negative regulator [
3], the underlying molecular basis of its signaling is poorly understood. A large body of evidence supports the hypothesis that CTLA-4 may down-regulate T-cell responses [
9‐
11]. Moreover, the majority of cancer cells either have low immunogenicity, lack costimulatory molecules, or both [
12,
13]. Therefore,
CTLA-4 may contribute to NPC development by controlling an individual's immune response.
An A→G dimorphism at position 49 in
CTLA-4 exon 1 (rs231775) has been reported by Nistico [
14], which causes an amino acid change (threonine to alanine) in the peptide leader sequence of the CTLA-4 protein [
15]. Recent studies found that this polymorphism may influence the ability of CTLA-4 to bind with B7.1 and subsequently, may affect T-cell activation [
16,
17]. These results suggest that a G allele instead of an A allele at position +49 can attenuate the CTLA-4-driven down-regulation of T-cell responses [
16,
18,
19]. However, the results of studies on the association between the +49 A > G polymorphism and the risk of cancers have been conflicting. So in order to summarize and clarify the published data we have performed a meta-analysis, using all eligible case-control studies to assess the association between the
CTLA-4 +49 A > G polymorphism and cancer risk.
Discussion and Conclusions
In this meta-analysis, which includes 22 independent case-control studies with 32 data sets, we found that the carriers of the CTLA-4 +49 (GA+AA) variant genotypes had a 1.24-fold increased risk of cancer in the dominant genetic model. These results support the hypothesis that polymorphisms of CTLA-4 play an important role in the development of cancer. However, we did not find evidence of significant associations in subgroup analyses for individual types of cancers, such as colorectal cancer, gastric cancer and non-solid tumors.
The immune system is a complex network that has evolved to protect humans against infectious agents and tumor growth. T-cells and natural killer (NK) cells are the major anti-tumor factors. Given that the activation of T-cells requires two signals, the CD28 costimulatory pathway has been shown to play a critical role in the induction and regulation of autoreactive T-cells. Furthermore, the human
CTLA4 and
CD28 genes are located in the same chromosome region and are closely linked and separated by only 130 kb [
43]. The gene structure of
CTLA4 is very similar to that of
CD28, except for 3' and 5' flanking sequences. All these data suggest that CTLA-4 and CD28 may be members of the same pathway, but execute different functions. Several groups found that CTLA-4 binds to the same ligands as CD28, i.e. CD80 and CD86 molecules, but has at least a 20-fold greater affinity [
44]. In contrast to CD28, CTLA-4 does not provide a positive signal for T-cell activation. Thus, CTLA-4 may contribute to the down-regulation of anti-tumor immune responses via interference with the CD28 costimulatory pathway. Moreover, CTLA-4 has been reported to increase TGF production, engage negative signaling pathways, inhibit lipid-raft and disturb TCR-induced stop signals [
11,
45,
46]. Nistico and his colleagues reported a functional polymorphism in
CTLA4 exon 1 which causes a threonine to alanine amino acid exchange in this protein's leader sequence [
14]. We noted the impact of the
CTLA4 exon 1 + 49 A/G dimorphism on immune regulation after T-cell stimulation. Several studies found that the surface expression and intracellular distribution of CTLA-4 differ between the two genotypes [
18,
19]. Results of the T-cell proliferation and B7.1 binding capability studies by Sun
et al. suggest that the
G allele at this position is correlated with increased T-cell activation [
16].
This study evaluated the associations of CTLA-4 +49A/G polymorphisms with different cancers. We found that this polymorphism was associated with an increased risk of developing solid tumors (including lung caner, breast cancer, colorectal cancer, gastric cancer, skin cancer, thymoma, nasopharyngeal carcinoma, cervical squamous cell carcinoma, esophageal cancer, oral squamous cell carcinoma, HBV-related hepatocellular carcinoma, and renal cell cancer), but not non-solid tumors, suggesting that the CTLA-4 gene plays different roles in the carcinogenesis of these two types of tumors. In our stratified analysis for ethnicity, the CTLA-4 +49G > A variant genotypes (GA + AA) were associated with an increased risk of cancer in Caucasians (OR = 1.29, 95% CI = 1.13-1.47, P = 0.0002), Chinese (OR = 1.23, 95% CI = 1.15-1.31, P < 0.00001), and Asians (OR = 1.23, 95% CI = 1.16-1.32, P < 0.00001), suggesting that the different genetic backgrounds of the different populations may to some extent explain the different risk estimates associated with the variant CTLA-4 genotypes. It seems that certain populations may have a higher susceptibility to cancer because they have higher frequencies of the variant genotypes +49G > A (GA + AA). Potential publication biases may exist in this meta-analysis, because studies with negative results are less likely to be published. Because only four out of 32 datasets were population-based case-control studies, with the others being hospital-based case-control studies, the study subjects may also not be representative of the general population. This could lead to selection bias.
In conclusion, our meta-analysis found evidence for an association between CTLA-4 +49A/G polymorphisms and multiple cancers in the general population, particularly for solid tumors. Due to the limitations of meta-analyses, larger association studies or multi-centric case-control studies are needed to confirm these findings.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JZ and XY participated study design and drafted the manuscript. JL carried out bioinformatics analysis and critically revised the manuscript. LJ and MX performed the statistical analysis. BB participated in the critical revision of the manuscript. YZ conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.